← All diseases Brain and nervous system

Multiple sclerosis (progressive)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchEvidence of the highest level only (104)Meta-analysis (24)Treatment guideline (1)Randomized trial (43)Systematic review (21)Phase 3 Study (15)Clinical trial (370)Review article (234)Early study (phase 1 or 2) (22)Case report (83)Laboratory or animal study (21)Commentary or editorial (19) Studies currently recruiting participants only (33)

Filter

Publications and studies (1543)

• Propionic acid promotes neurite recovery in damaged multiple sclerosis neurons. (2024/06/03) ♡
• Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments. (2024/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The CD40/CD40 ligand dyad and its downstream effector molecule ISG54 in relating acute neuroinflammation with persistent, progressive demyelination. (2024/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials. (2024/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Multiple Sclerosis Part 1: Essentials and the McDonald Criteria. (2024/05/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Prevalence and Associated Clinical Characteristics of Walking-Related Motor, Cognitive, and Fatigability in Progressive Multiple Sclerosis: Baseline Results From the CogEx Study. (2024/05/01) ♡
• Essential trace element levels in multiple sclerosis: Bridging demographic and clinical gaps, assessing the need for supplementation. (2024/05/01) ♡
• Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis. (2024/04/10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Impact of Multiple Sclerosis Subtypes on Pain Management in Patients With Trigeminal Neuralgia After Stereotactic Radiosurgery: An International Multicenter Analysis. (2024/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Multiple Sclerosis: An Emergency Medicine-Focused Narrative Review. (2024/04/01) ♡
• The relationship between dietary profile and adherence to the Mediterranean diet with EDSS and quality of life in multiple sclerosis patients: a retrospective cross-sectional study. (2024/04/01) ♡
• Perspective: The Impact of Fasting and Caloric Restriction on Neurodegenerative Diseases in Humans. (2024/04/01) ♡
• Comparing the Pathology, Clinical, and Demographic Characteristics of Younger and Older-Onset Multiple Sclerosis. (2024/03/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial. (2024/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Proximity extension assay-based proteomics studies in neurodegenerative disorders and multiple sclerosis. (2024/03/01) ♡
• Dehydration associates with lower urinary tract symptoms in progressive multiple sclerosis. (2024/03/01) ♡
• Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry. (2024/03/01) ♡
• Associations between cortical lesions, optic nerve damage, and disability at the onset of multiple sclerosis: insights into neurodegenerative processes. (2024/03/01) ♡
• Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study. (2024/03/01) ♡
• Sex Differences under Vitamin D Supplementation in an Animal Model of Progressive Multiple Sclerosis. (2024/02/17) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Biomarkers of disability worsening in inactive primary progressive multiple sclerosis. (2024/02/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Advances in Multiple Sclerosis Neurotherapeutics, Neuroprotection, and Risk Mitigation Strategies. (2024/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion. (2024/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical and Treatment Considerations for the Pediatric and Aging Patients with Multiple Sclerosis. (2024/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Pathophysiology, Diagnosis, Treatment and Emerging Neurotherapeutic Targets for Progressive Multiple Sclerosis: The Age of PIRA. (2024/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium. (2024/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation. (2024/02/01) ♡
• Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. (2024/02/01) ♡
• A cross-sectional study of MRI features and the gut microbiome in pediatric-onset multiple sclerosis. (2024/02/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis. (2024/02/01) ♡
• Ocrelizumab in highly disabled progressive multiple sclerosis patients. (2024/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Multiple sclerosis and seizures: A retrospective observational study in a multiple sclerosis autoimmunity center of excellence. (2024/02/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod. (2024/02/01) ♡
• Multiple sclerosis clinical forms classification with graph convolutional networks based on brain morphological connectivity. (2024/01/18) ♡
• The nature of memory impairment in multiple sclerosis: understanding different patterns over the course of the disease. (2024/01/16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Non-lesional white matter changes depicted by q-space diffusional MRI correlate with clinical disabilities in multiple sclerosis. (2024/01/15) ♡
• Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. (2024/01/09) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study. (2024/01/09) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Transverse Myelitis in the Setting of Enterobius vermicularis (Pinworm) Infection: Case Report. (2024/01/01) ♡
• Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis. (2024/01/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Cell replacement therapy with stem cells in multiple sclerosis, a systematic review. (2024/01/01) ♡
• Impairment of daily occupations in multiple sclerosis: analysis of neuroimaging, general and social cognition, and reserve. (2024/01/01) ♡
• Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis. (2024/01/01) ♡
• Exploratory 5-year follow-up study of retinol, tocopherols, and carotenoids in multiple sclerosis. (2024/01/01) ♡
• Utility of the 2023 international MOGAD panel proposed criteria in clinical practice: An institutional cohort. (2024/01/01) ♡
• The influence of personality in persons with MS. (2024/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Toward identifying key mechanisms of progression in multiple sclerosis. (2024/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis. (2024/01/01) ♡
• Seasonality and clinical characteristics of MS in an equatorial country. (2024/01/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Does non-invasive brain stimulation improve spatiotemporal gait parameters in people with multiple sclerosis? A systematic review and meta-analysis. (2024/01/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.